This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ImmunoGen, Inc. Announces Presentations At Upcoming AACR-NCI-EORTC Anticancer Conference

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its ADC technology, today announced the Company-related poster presentations accepted for the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting to be held October 19-23, 2013 in Boston, MA.

The first clinical data with SAR566658 are to be reported. This ADC is a potential new treatment for ovarian, pancreatic, breast and other CA6-positive cancers in development by Sanofi through a collaboration with the Company. Additionally, ImmunoGen scientists will report on the Company’s new platform of DNA-acting cytotoxic agents for use in ADCs as well as on an additional linker ImmunoGen has added to its already extensive technology portfolio.

Poster Presentations

On Sunday, Oct. 20, the first SAR566658 clinical data are scheduled to be presented from 12:30-3:00 pm and 6:30-7:30 pm ET.
  • “A phase I first-in-human study of SAR566658, an anti-CA-6-antibody-drug conjugate in patients with CA6-positive advanced solid tumors” (Poster Session A, Abstract #A73).

On Tuesday, Oct. 22, 12:30-3:00pm ET, three posters on ImmunoGen’s expanding ADC technology portfolio are scheduled to be presented:
  • “New Class of DNA-alkylating agents with a suitable tolerability profile created for use in antibody-drug conjugates (ADCs)” (Poster Session C, Abstract #C160).
  • “Antibody-Drug Conjugates (ADCs) with novel IGN DNA-alkylating agents display potent antigen-specific activity against hematologic and solid tumor xenograft models” (Poster Session C, Abstract #C162).
  • “New tri-glycl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs)” (Poster Session C, Abstract #C164).

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla ®, which is marketed in the US by Genentech and is also gaining approvals internationally. ImmunoGen has four wholly owned clinical-stage product candidates, with additional compounds in the clinic through its partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at

Kadcyla ® is a registered trademark of Genentech, Inc., a member of the Roche Group.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products and new anticancer technologies. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2013 and other reports filed with the Securities and Exchange Commission.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%
TSLA $240.76 0.00%
YHOO $36.60 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs